Active Ingredient(s): Risankizumab-rzaa
FDA Approved: * April 23, 2019
Pharm Company: * ABBVIE INC
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Skyrizi Overview

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A).[5] Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in the European Union,[4] the United States,[3][6] and Canada[7] for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. In Japan,...

Read more Skyrizi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Skyrizi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 150mg/ml, 75mg/0.83ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Skyrizi: (3 results)

Sorted by National Drug Code
  • 0074-1050 Skyrizi 150 mg/ml Subcutaneous Injection by Abbvie Inc.
  • 0074-2042 SkyriziSkyrizi Kit by Abbvie Inc.
  • 0074-2100 Skyrizi 150 mg/ml Subcutaneous Injection by Abbvie Inc.

Other drugs which contain Risankizumab-rzaa or a similar ingredient: (1 result)